Modality
mAb
MOA
DLL3 ADC
Target
SMN2
Pathway
DDR
MDSMSET
Development Pipeline
Preclinical
Oct 2020
→ Dec 2031
PreclinicalCurrent
NCT06202992
109 pts·MDS
2020-10→2031-12·Recruiting
109 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-12-145.7y awayInterim· MDS
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Recruit…
Catalysts
Interim
2031-12-14 · 5.7y away
MDS
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06202992 | Preclinical | MDS | Recruiting | 109 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 | |
| GLP-3342 | Galapagos | Phase 1/2 | PLK4 |